
After drugmaker Novo Nordisk tweaked its diabetes drug Ozempic into Wegovy — a formulation expressly designed to help users shed pounds — sales of both drugs skyrocketed. Other pharmaceutical giants took notice, and over the past weekend the results of multiple clinical trials from would-be competitors were unveiled at this year’s annual meeting of the… read on > read on >